title: [Recurrent lepromatous leprosy in conventional triple therapy: value of the rifampicin-ofloxacin combination].
authors.forename: S
authors.initials: S
authors.lastname: Marlier
authors.forename: F
authors.initials: F
authors.lastname: Carsuzaa
authors.forename: J P
authors.initials: JP
authors.lastname: De Jaureguiberry
authors.forename: M
authors.initials: M
authors.lastname: Galzin
authors.forename: E
authors.initials: E
authors.lastname: Carloz
authors.forename: P
authors.initials: P
authors.lastname: Carli
authors.forename: A
authors.initials: A
authors.lastname: Chagnon
mesh_terms: D000368:Aged; D004359:Drug Therapy, Combination; D006801:Humans; D007917:Leprostatic Agents / Q000627:therapeutic use*; D015440:Leprosy, Lepromatous / Q000188:drug therapy*; D008297:Male; D015242:Ofloxacin / Q000627:therapeutic use*; D012008:Recurrence; D012293:Rifampin / Q000627:therapeutic use*
chemical_list: D007917:Leprostatic Agents; D015242:Ofloxacin; D012293:Rifampin
vernacular_title: Lepre lepromateuse recidivante sous tritherapie conventionnelle: interet de l'association rifampicine-ofloxacine.